Garnett and colleagues review principles that underpin the pre-clinical development of genomics-guided cancer medicines, challenges that limit their impact, and new opportunities, such as CRISPR-based screening, for refining and extending their use.
- Hayley E. Francies
- Ultan McDermott
- Mathew J. Garnett